REGN

Regeneron Pharmaceuticals

$790.74

-0.70% Oct 16 close

Health CareS&P 500 Compare Technicals

1M 3M 6M 1Y 2Y

REGNSPY

+5.9%

+2.1%

+17.0%

+5.6%

YTD

+2.8%

+39.6%

Live chart

Loading live chart…

What they do

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

Momentum

48th percentile in sector

12-1 return: +16.9%
Percentile within its GICS sector across the S&P 1500.

Growth

75th percentile in sector

B+

Revenue growth (YoY): +16.7%
Percentile within its GICS sector across the S&P 1500.

Value

62nd percentile in sector

B-

Forward E/P: 7.8% · EBITDA/EV: 6.4%
Percentile within its GICS sector across the S&P 1500.

Profitability

75th percentile in sector

B+

Profit margin: +27.9% · Return on equity: +14.0%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

ranked 84 of 499 · 12-month momentum 42.9%

Momentum Blend

Not in the current book

New Highs Growth

Outside this model's universe or screens

Coteau Long Book

Not in the current book

News

More news

Why Should You Think About Vertex Differently Now?

Trefis · Oct 20

Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results

Insider Monkey · Oct 19

Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?

Zacks · Oct 19

Key stats

52-week range$566.27 – $852.03

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Leans undervalued

Model read-out from the numbers below, not advice. Score +2 (DCF counts double).

▲DCF (base case)above the price by 20%

•Piotroski F-score5/9

▲Net debt / EBITDA-1.0x

Discounted cash flow

Bear

$619

-22%

growth 1% · disc. 10.2% · term. 2.0%

Base

$950

+20%

growth 6% · disc. 9.2% · term. 2.5%

Bull

$1,401

+77%

growth 9% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Not enough data to run a reverse DCF.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6×

–

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1×

–

Price / book

sector median 3.5×

–

FCF yield

sector median 4.1%

–

Quality & financial health

Gross margin

97.4%

Operating margin

24.7%

FCF margin

30.1%

Net margin

27.9%

Return on equity

13.7%

Return on invested capital

11.8%

Net debt / EBITDA

-1.0×

Current ratio

3.3×

Interest cover

69.4×

Cash conversion (OCF/NI)

1.1×

Piotroski F-score 5/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FY	Revenue	Net income	Free cash flow
2025	$14.3B	$4.5B	$5.0B
2024	$14.2B	$4.4B	$4.4B
2023	$13.1B	$4.0B	$4.6B
2022	$12.2B	$4.3B	$5.0B
2021	$16.1B	$8.1B	$7.1B
2020	$8.5B	$3.5B	$2.6B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +5.6%.

Earnings

Next report: –

No EPS history available.

Stats refreshed – ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it works Terms Privacy Data status Send feedback

Beta 0.9 · Oct 21, 2026